Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: Aug 13, 2025
- Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance -
Read more at globenewswire.com
